Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Davide Nappi, Gerardo Musuraca, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Giovanni Martinelli

Blood (2022) 140 (Supplement 1): 13248–13249.

https://doi.org/10.1182/blood-2022-170561

Published: 2022

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143082

Published: 2020

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Paola Tacchetti, MD, Lucia Pantani, MD, Valerio De Stefano, MD, Elena Zamagni, MD, Jacopo Peccatori, MD, Annalisa Pezzi, Statistician, Catello Califano, MD, Andrea Nozza, MD, Patrizia Tosi, MD, Carolina Terragna, PhD, Fabrizio Ciambelli, MD, Delia Cangini, MD, Piero Galieni, MD, Clotilde Cangialosi, MD, Giovanni De Sabbata, MD, Francesca Elice, MD, Antonio Palumbo, MD, Michele Cavo, MD

Blood (2014) 124 (21): 196.

https://doi.org/10.1182/blood.V124.21.196.196

Published: 2014

Journal Articles

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Gerardo Musuraca, MD, PhD, Serena De Matteis, Roberta Napolitano, Francesco Fabbri, Delia Cangini, MD, Michela Ceccolini, MD, Maria Benedetta Giannini, MD, Alessandro Lucchesi, MD, Sonia Ronconi, MD, Cristina Papayannidis, MD, Viviana Guadagnuolo, Giovanni Martinelli, MD, Paolo Savini, MD, Monica Tani, MD, Patrizia Tosi, MD, Dino Amadori, MD, Pier Paolo Fattori, MD, Wainer Zoli, Silvia Carloni

Blood (2013) 122 (21): 2289.

https://doi.org/10.1182/blood.V122.21.2289.2289

Published: 2013

Journal Articles

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Blood (2009) 114 (22): 349.

https://doi.org/10.1182/blood.V114.22.349.349

Published: 2009

Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Blood (2008) 112 (11): 1662.

https://doi.org/10.1182/blood.V112.11.1662.1662

Published: 2008

Journal Articles

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

Patrizia Tosi, Elena Zamagni, Delia Cangini, Paola Tacchetti, Francesco Di Raimondo, Lucio Catalano, Alfonso D'Arco, Sonia Ronconi, Claudia Cellini, Massimo Offidani, Giulia Perrone, Michela Ceccolini, Annamaria Brioli, Sante Tura, Michele Baccarani, Michele Cavo

Blood (2006) 108 (12): 3951–3952.

https://doi.org/10.1182/blood-2006-07-033571

Published: 2006

Journal Articles

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

Michele Cavo, Nicoletta Testoni, Carolina Terragna, Elena Zamagni, Paola Tacchetti, Chiara Nicci, Matteo Renzulli, Elena Montanari, Giulia Perrone, Delia Cangini, Tiziana Grafone, Michela Ceccolini, AnnaMaria Brioli, Giovanni Martinelli, Patrizia Tosi, Michele Baccarani

Blood (2006) 108 (11): 3081.

https://doi.org/10.1182/blood.V108.11.3081.3081

Published: 2006

Journal Articles

Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.

Elena Zamagni, Cristina Nanni, Patrizia Tosi, Stefano Fanti, Delia Cangini, Paolo Castellucci, Paola Tacchetti, Giulia Perrone, Michela Ceccolini, Mohsen Farsad, Michele Baccarani, Michele Cavo

Blood (2005) 106 (11): 3492.

https://doi.org/10.1182/blood.V106.11.3492.3492

Published: 2005

Journal Articles

Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.

Patrizia Tosi, MD, Elena Zamagni, MD, Delia Cangini, MD, Paola Tacchetti, MD, Massimo Offidani, MD, Sonia Ronconi, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Michele Baccarani, MD, Sante Tura, MD, Michele Cavo, MD

Blood (2005) 106 (11): 3461.

https://doi.org/10.1182/blood.V106.11.3461.3461

Published: 2005

Journal Articles

Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.

Michele Cavo, MD, Elena Zamagni, MD, Patrizia Tosi, MD, Delia Cangini, MD, Paola Tacchetti, MD, Claudia Cellini, MD, Nicoletta Testoni, PhD, Chiara Nicci, PhD, Antonio de Vivo, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Michele Baccarani, MD

Blood (2005) 106 (11): 5474.

https://doi.org/10.1182/blood.V106.11.5474.5474

Published: 2005

Journal Articles

Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.

Carolina Terragna, Matteo Renzulli, Nicoletta Testoni, Chiara Nicci, Tiziana Grafone, Patrizia Tosi, Elena Zamagni, Claudia Cellini, Delia Cangini, Paola Tacchetti, Giulia Perrone, Simona Soverini, Giovanni Martinelli, Michele Baccarani, Michele Cavo

Blood (2005) 106 (11): 5072.

https://doi.org/10.1182/blood.V106.11.5072.5072

Published: 2005

Journal Articles

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Michele Cavo, Elena Zamagni, Patrizia Tosi, Paola Tacchetti, Claudia Cellini, Delia Cangini, Antonio de Vivo, Nicoletta Testoni, Chiara Nicci, Carolina Terragna, Tiziana Grafone, Giulia Perrone, Michela Ceccolini, Sante Tura, Michele Baccarani, for the writing committee of the Bologna 2002 study

Blood (2005) 106 (1): 35–39.

https://doi.org/10.1182/blood-2005-02-0522

Published: 2005

Journal Articles

Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.

Patrizia Tosi, MD, Elena Zamagni, MD, Claudia Cellini, MD, Delia Cangini, MD, Paola Tacchetti, MD, Giulia Perrone, MD, Sante Tura, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2004) 104 (11): 4898.

https://doi.org/10.1182/blood.V104.11.4898.4898

Published: 2004

Journal Articles

Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

Michele Cavo, Claudia Cellini, Elena Zamagni, Patrizia Tosi, Delia Cangini, Paola Tacchetti, Antonio De Vivo, Giulia Perrone, Roberto Massimo Lemoli, Sante Tura, Michele Baccarani

Blood (2004) 104 (11): 536.

https://doi.org/10.1182/blood.V104.11.536.536

Published: 2004

Journal Articles

Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Michele Cavo, Paola Tacchetti, Elena Zamagni, Patrizia Tosi, Delia Cangini, Claudia Cellini, Nicoletta Testoni, Antonio De Vivo, Giulia Perrone, Sante Tura, Michele Baccarani

Blood (2004) 104 (11): 1489.

https://doi.org/10.1182/blood.V104.11.1489.1489

Published: 2004

Journal Articles

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

Blood (2003) 102 (5): 1588–1594.

https://doi.org/10.1182/blood-2002-12-3789

Published: 2003

NARROW

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.

Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.

Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.

Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.

Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only